MEDIPOST preparing for Phase 3 clinical trials of its umbilical cord stem cell product, Cartistem, appoints 5 new executives
South Korea's MEDIPOST, Inc., a company developing stem cell-based therapeutics, has announced the appointment of five senior executives, which they say will bring decades of expertise in biologics and cell & gene...
